DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

Organogenesis Holdings Sees FY20 Sales $273M-$277M vs $271.38M Est.

For the twelve months ending December 31, 2020, the Company expects: Net revenue of between $273 million and $277 million, representing growth of

Benzinga · 03/09/2020 20:08

For the twelve months ending December 31, 2020, the Company expects:

  • Net revenue of between $273 million and $277 million, representing growth of approximately 5% to 6% year-over-year, as compared to net revenue of $261 million for the twelve months ended December 31, 2019.
  • The 2020 net revenue guidance range assumes:

    --Net revenue from Advanced Wound Care products of between $229 million and $231 million, representing growth of approximately 4% to 5% year-over-year as compared to net revenue of $221 million for the twelve months ended December 31, 2019.

    -- Net revenue from Surgical & Sports Medicine products of between $44 million and $46 million, representing growth of approximately 9% to 14% year-over-year as compared to net revenue of $40 million for the twelve months ended December 31, 2019.

    -- Net revenue from the sale of PuraPly products of between $118 million and $120 million, representing a decrease of approximately 5% to 7% year-over-year, as compared to net revenue of $127 million for the twelve months ended December 31, 2019.